TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04688060

Intervention type: DIAGNOSTIC_TEST
Intervention: Falls Efficacy Scale-International (FES-I)
Description: The FES-1 was used to assess the fear of falling level of participants about falling during indoor or outdoor activities. It has 16 items scored on a four-point Likert scale. The Turkish validated version of the FES-I was used in this study. The total score (sum of the 16 responses) ranging from 16 to 64 points was used for data analysis. A higher score indicates better mobility performance. A cut-off score of 27 points on the 16- item FES-I was used to differentiate high concern for falling from low concern
Study: NCT05757440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Icon resin application
Description: Application of the low-viscosity resin infiltration (Icon) to the white spot enamel lesions
Study: NCT02748421

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lumera Microscope with OCT RESCAN
Description: macular membrane dissection with OCT RESCAN

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional Microscope
Description: macular membrane dissection without OCT RESCAN
Study: NCT03550443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl
Description: Bardoxolone methyl 5 mg capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules containing an inert placebo
Study: NCT00425698

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant erythropoietin alpha (rHuEPO alpha)
Description: Erythropoietin alpha 3 x 40.000 IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo 3x IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 3x IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
Study: NCT01835977

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Irreversible Electroporation (Nanoknife)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Irreversible Electroporation (Nanoknife)
Study: NCT03668496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: Drug delivery cycle is 3 weeks, and in the experimental group,200 mg shr-1210 was given with Carboplatin and Paclitaxel in the first day of each cycle, with intravenous drip.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The placebo
Description: in the control group,placebo was given with Carboplatin and Paclitaxel in the first day of each cycle, with intravenous drip.
Study: NCT01684696

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual experience

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Videos
Study: NCT01157338

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: diagnostic cardiac catheterization
Description: coronary intervention: angiography

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic cardiac catheterization
Description: cardiac catheterization: angioplasty
Study: NCT04057924

Intervention type: OTHER
Intervention: abstention from CIN2 treatment and surveillance for at least 2 years
Description: Non-interventional monocentric prospective study taking place at the Bordeaux University Hospital where women with a CIN2 meeting the eligibility criteria will benefit from abstention from treatment and surveillance for at least 2 years
Study: NCT02626429

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino acid intake
Description: Amino acid intakes will be varied at 0.2-2.6 g/kg/day
Study: NCT00916201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: URB597
Description: 10 mg / d for 5 days, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal Insulin
Description: 160 IU / d for 5 days, intranasal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol CR
Description: 320 mg / d for 5 days, orally
Study: NCT02546258

Intervention type: DEVICE
Group type: OTHER
Intervention: A Fungal Nail Treatment
Description: treats the signs of mild fungal nail infections
Study: NCT03877315

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stemmed shoulder arthroplasty, Biomet Comprehensive® Total Shoulder System.
Description: A total shoulder prosthesis used in treating glenohumeral osteoarthritis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stemless shoulder arthroplasty, Biomet Comprehensive® Nano Shoulder System.
Description: A total shoulder prosthesis used in treating glenohumeral osteoarthritis
Study: NCT03492957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: A tailored, person-centred, 12-week, chair-based exercise intervention to increase physical activity and fitness. Dose: one face-face session with a qualified physiotherapist plus two independent sessions per week. This is combined with education on self-management, self-efficacy and lifestyle change.
Study: NCT03660865

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light Adjustable lens (LAL) and Light Delivery Device (LDD)
Description: Primary eye will receive Light adjustable lens with Light delivery Device treatments

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control IOL
Description: Fellow eye will receive control IOL
Study: NCT02250508

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Optivate® (Human Coagulation Factor VIII)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Haemate P® (Human Coagulation Factor VIII)
Study: NCT03985943

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemolizumab
Description: Nemolizumab
Study: NCT01597765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: curcuminoids, N-acetylcysteine, deferiprone and vitamin E
Description: receiving curcuminoids 500 mg/day, N-acetylcysteine 200 mg/day deferiprone 50 mg/kg/day and vitamin E 400 IU/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: curcuminoids, N-acetylcysteine, deferiprone and vitamin E
Description: receiving curcuminoids 500 mg/day, N-acetylcysteine 200 mg/day deferiprone 50 mg/kg/day and vitamin E 400 IU/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcuminoids and alpha-tocopherol
Description: group 1: receiving curcuminoids 500 mg/day, N-acetylcysteine 200 mg/day and deferiprone 50 mg/kg/day group 2: receiving vitamin E 400 IU/day, N-acetylcysteine 200 mg/day and deferiprone 50 mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcuminoids and alpha-tocopherol
Description: group 1: receiving curcuminoids 500 mg/day, N-acetylcysteine 200 mg/day and deferiprone 50 mg/kg/day group 2: receiving vitamin E 400 IU/day, N-acetylcysteine 200 mg/day and deferiprone 50 mg/kg/day
Study: NCT02459431

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 21 G needle group
Description: Patients with a clinico radiologic suspicion of sarcoidosis will undergo endobronchial ultrasound guided transbronchial needle aspiration with 21 G needle, by random assignment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 22 G needle group
Description: Patients with a clinico radiologic suspicion of sarcoidosis will undergo endobronchial ultrasound guided transbronchial needle aspiration with 22 G needle, by random assignment
Study: NCT02029755

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transversus abdominis plane block
Description: bilateral ultrasound-guided transversus abdominis plane block, with 20 ml of 0.25% ropivacaine at each side after the induction of general anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local infiltration
Description: local anesthetics infiltration at surgical wound with 20 ml of 0.5% ropivacaine before wound closure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient controlled analgesia
Description: postoperative analgesia with intravenous patient controlled analgesia with morphine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient controlled analgesia
Description: postoperative analgesia with intravenous patient controlled analgesia with morphine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient controlled analgesia
Description: postoperative analgesia with intravenous patient controlled analgesia with morphine
Study: NCT02766439

Intervention type: DRUG
Intervention: etanercept
Description: 25-mg etanercept injection subcutaneously twice a week
Study: NCT00453037

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: structured educational program
Description: structured education and evaluation of hypertensive patients in a design similar to the DAFNE study design. Behavioural intervention follows the Dusseldorf-educational program

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: participation in the educational program after 6 months
Description: Control group consisting of patients randomly assigned to participate in the educational program 6 months later than the active group
Study: NCT04610619

Intervention type: OTHER
Intervention: Immunological challenge
Description: In vitro immunological study of subjects with RYR1 related MH/rhabdomyolysis. Studying of circulating cytokines and cytokines production after in vitro stimulation
Study: NCT01555853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Study: NCT02888691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High carbohydrate diet
Study: NCT04082845

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Web-based patient education
Study: NCT04534179

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vacuum myofascial therapy and physical activity program.
Description: This group will treated five times with the analgesic program of physium therapy. Each maneuver was performed once per session by slow and progressive. The whole procedure lasted no more than 30 minutes.~Then they carried out the physical activity program
Study: NCT02394028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrolizumab
Description: Etrolizumab will be administered as per regimen specified in individual arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Etrolizumab-matching placebo will be administered as per regimen specified in individual arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Etrolizumab-matching placebo will be administered as per regimen specified in individual arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Etrolizumab-matching placebo will be administered as per regimen specified in individual arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Etrolizumab-matching placebo will be administered as per regimen specified in individual arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Etrolizumab-matching placebo will be administered as per regimen specified in individual arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Etrolizumab-matching placebo will be administered as per regimen specified in individual arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Etrolizumab-matching placebo will be administered as per regimen specified in individual arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Etrolizumab-matching placebo will be administered as per regimen specified in individual arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Etrolizumab-matching placebo will be administered as per regimen specified in individual arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Etrolizumab-matching placebo will be administered as per regimen specified in individual arms.
Study: NCT01646255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Transdermal Patch~Content:~4 mg /24 h (20 cm\^2), 6 mg /24 h (30 cm\^2), 8 mg /24 h (40 cm\^2)~For advanced-stage Parkinson's Disease, subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 12 week maintenance period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Transdermal Patch~Size:~20 cm\^2, 30 cm\^2, 40 cm\^2~Subjects randomized to placebo received matching placebo patches

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: L-dopa
Description: Subject must be on a stable dose of L-dopa (either short-acting or sustained release \[in combination with benserazide or carbidopa\]) of at least 200 mg/day, administered in at least 2 intakes, for at least 28 days prior to Baseline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-dopa
Description: Subject must be on a stable dose of L-dopa (either short-acting or sustained release \[in combination with benserazide or carbidopa\]) of at least 200 mg/day, administered in at least 2 intakes, for at least 28 days prior to Baseline.
Study: NCT01731197

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dry-Blended Beverage

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dry-Blended Beverage

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dry-Blended Beverage
Study: NCT02391480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-075
Description: ABBV-075 Oral tablets
Study: NCT00674752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 250 mg oral capsule 30 minutes prior to bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 500 mg oral capsule 30 minutes prior to bedtime
Study: NCT02391480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-075
Description: ABBV-075 Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-075
Description: ABBV-075 Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax tablets, film-coated
Study: NCT02111603

Intervention type: DRUG
Group type: OTHER
Intervention: Colesevelam
Description: Subjects will receive 1875 mg of Colesevelam orally twice daily for 10 days
Study: NCT01731197

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dry-Blended Beverage
Study: NCT05567276

Intervention type: BEHAVIORAL
Intervention: Non-Violent Resistance parental training
Description: Non-Violent Resistance parental training
Study: NCT04187339

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM395
Description: NGM395 Dose 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM395
Description: NGM395 Dose 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM395
Description: NGM395 Dose 3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM395
Description: NGM395 Dose 4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM395
Description: NGM395 Dose 5

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM395
Description: NGM395 Dose 6

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02556463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI9197
Description: Subjects will receive MEDI9197 (every 4 weeks) as monotherapy (or MEDI9197 every 8 weeks + durvalumab every 4 weeks)(PA6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI9197
Description: Subjects will receive MEDI9197 (every 4 weeks) as monotherapy (or MEDI9197 every 8 weeks + durvalumab every 4 weeks)(PA6)
Study: NCT02369211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen (Ofirmev)
Description: The patient was administered IV Ofirmev during anesthesia and then 3 more IV doses (1g each) every 6 hours up to 24 hrs.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patient was administered IV Placebo during anesthesia and then 3 more doses of IV Placebo every 6 hours up to 24 hrs.
Study: NCT02556463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI9197
Description: Subjects will receive MEDI9197 (every 4 weeks) as monotherapy (or MEDI9197 every 8 weeks + durvalumab every 4 weeks)(PA6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI9197
Description: Subjects will receive MEDI9197 (every 4 weeks) as monotherapy (or MEDI9197 every 8 weeks + durvalumab every 4 weeks)(PA6)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: Subjects will receive durvalumab every 4 weeks
Study: NCT00674752

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo oral capsule 30 minutes prior to bedtime
Study: NCT00571298

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extrapleural pneumonectomy (EPP)
Description: Resection of the lung, the lining of the lung (pleura), the covering of the heart (pericardium), and the muscle that separates the chest and abdomen (diaphragm)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given after the tumor is removed as a bath (perfusion) for one-hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given after the tumor is removed as a bath (perfusion) for one-hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given after the tumor is removed as a bath (perfusion) for one-hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Given after the tumor is removed as a bath (perfusion) for one-hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Given after the tumor is removed as a bath (perfusion) for one-hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Given after the tumor is removed as a bath (perfusion) for one-hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine
Description: Given intravenously before perfusion chemotherapy and then 2 hours after the first dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine
Description: Given intravenously before perfusion chemotherapy and then 2 hours after the first dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine
Description: Given intravenously before perfusion chemotherapy and then 2 hours after the first dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium thiosulfate
Description: Given intravenously immediately at the end of perfusion chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium thiosulfate
Description: Given intravenously immediately at the end of perfusion chemotherapy
Study: NCT04534179

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity program.
Description: Active Comparator: Physical activity The exercise protocol would last 5 weeks, performing 3 exercise sessions per week, with an effective work time of 20 minutes per session. The exercises would be directly focused on activating the core stabilizing muscles.
Study: NCT02672059

Intervention type: OTHER
Intervention: Observation
Description: No intervention
Study: NCT01092780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7288
Description: one or two 10 mg capsules, orally, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7288
Description: one or two 10 mg capsules, orally, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7288
Description: one or two 10 mg capsules, orally, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7288
Description: one or two 10 mg capsules, orally, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-7288
Description: one or two capsules, orally, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-7288
Description: one or two capsules, orally, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-7288
Description: one or two capsules, orally, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-7288
Description: one or two capsules, orally, single dose
Study: NCT01895569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be added to therapy for the first threre months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: In patients not well controlled (glycated hemoglobin \>6.5%) after three months of metformin, pioglitazone will be added.
Study: NCT00571298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium thiosulfate
Description: Given intravenously immediately at the end of perfusion chemotherapy
Study: NCT01092780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: two 100 mg tablets, orally, single dose
Study: NCT00571298

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pleurectomy/Decortication
Description: Resection of the lining of the lung (pleura), while the lung remains intact.
Study: NCT00040911

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electroacupuncture therapy
Study: NCT01092780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: two 100 mg tablets, orally, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: two 100 mg tablets, orally, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: two 100 mg tablets, orally, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to modafinil
Description: two 100 mg tablets, orally, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to modafinil
Description: two 100 mg tablets, orally, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to modafinil
Description: two 100 mg tablets, orally, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to modafinil
Description: two 100 mg tablets, orally, single dose
Study: NCT04353089

Intervention type: OTHER
Intervention: Basic life support courses
Description: 4 hours certified basic life support courses